MAMaryam Abbasi

Maryam Abbasi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Maryam Abbasi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Efficacy and Safety of mitapivat in a subset of hereditary hemolytic anemias: a systematic review, meta-analysis, and GRADE assessment of randomized controlled trials

    by Humayou Ahmed, Daniyal Zulfiqar, Maryam Abbasi, Kainat Mehmood, Maheen Hamid, Hafsa Ahsun, Mohammad Hassan, Muhammad Saad Khan, Sameen Fida, Muhammad Rayyan Humayun, et al.

  • Open Access

    Neurological manifestations of Erdheim-Chester disease and their management: A scoping review

    by Muhammad Saeed Qazi, Awais Ahmad, Mahreen Mukhtiar, Rizwana Noor, Hassan Ahmed, Shifa Ul Mehmood, Maryam Abbasi, Amna Siddiqui, Muhammad Hasanain, Zain Ul Abideen, et al.

    Background: Erdheim–Chester disease (ECD) is characterized by the excessive production and accumulation of histiocytes, particularly foamy histiocytes encircled by fibrosis, in various organs. ECD can affect a person’s long bones, skin, lungs, brain, heart, and other tissues and organs. Methods: In February 2024, we conducted a thorough literature search on main databases to find studies published between 2021 and 2024. We used keywords like “ECD CNS,” “ECD Neuro,” “Erdheim Chester Disease CNS,” “histiocytosis,” and “Erdheim Chester Disease Neurology.” We first produced 461 articles and then limited the selection process to 29 articles using an English language filter and an abstract analysis. In the end 16 articles were added in the review on ECD with neurological symptoms. Results: Ataxia, cranial neuropathies, and cognitive impairment were the main clinical findings. Histopathology showed that 88% of the cases had histiocyte infiltrates with CD68 + histiocytes, 50% had a BRAF mutation, and 83.3% had an expanding mass. The most common treatment was vemurafenib, followed by steroids, surgery, and chemotherapy. Results revealed 15.78% mortality, 26.31% progression, and 31.57% improvement or stabilization. In most cases, steroid medication proved useless; however, vemurafenib and radiation therapy helped some patients’ symptoms. Conclusion: An early diagnosis of the disease is important for timely intervention, to prevent fatal outcomes. Vemurafenib was the only drug which proved its efficacy against the disease, as compared to other drugs. This study presents valuable insights for the neurology of ECD and highlights the benefits of a comprehensive management for this complex condition.


  • Open Access

    Impact of Body Mass Index on Gastrointestinal Disorders: A Cross-sectional Study in a Pakistani Population

    by Shahid Ahmed, Hafeezullah Shaikh, Sajjad Jamil, Hamid Ali, Maryam Abbasi

    Background: The prevalence of obesity is on the rise globally. Pakistan ranks ninth out of 188 countries in terms of obesity. Literature regarding any potential role of obesity in gastrointestinal manifestations is limited. Besides, scarce information is available on possible connection between obesity and gastrointestinal pathology. This research, therefore, explores the impact of body mass index (BMI) on gastrointestinal symptoms and endoscopic discoveries. Methods: A cross-sectional study was conducted at Darul Sehat Hospital, Zubaida Medical Centre, and Liaquat National Hospital & Medical College, Karachi, Pakistan from 1st July 2017 to 30th November 2018. Patients scheduled to undergo endoscopy were surveyed before the procedure in which they were asked about demographics, comorbid, and gastrointestinal manifestations. The association between BMI and endoscopic findings and related gastrointestinal symptoms was assessed using Pearson chi square test and binary logistic regression. The significance level was set at 0.05. Results: A total of 2148 subjects were included in the study out of which 20.2% were overweight (BMI 23-24.9) and 20.9% subjects were obese (BMI >25). Both the gastrointestinal symptoms and endoscopic findings were found to be significantly associated with the BMI (p<0.05 for both). Moreover, binary logistic regression revealed obesity to be a significant contributor of abnormal endoscopic findings (adjusted odds ratio, AOR, 2.93; 95% confidence interval, CI, 2.35-3.65). Conclusion: Based on the study results, obesity was identified as a risk factor associated with gastrointestinal symptoms like gastro esophageal reflux disease (GERD) and other related gastrointestinal conditions such as erosive gastritis, duodenal ulcers, reflux esophagitis, and large hiatal hernia.